Aspira Women's Health Inc. · OTC:AWHL
Aspira Women's Health — Investor Presentation (September 2022)
20 slides from Aspira Women's Health's investor presentation, September 2022

Slide 1: Transforming the State of Women's Gynecological Health
Transforming the State of Women’s Gynecological Health… Starting with Ovarian Cancer Corporate Presentation | September 2022 Copyright (C) Aspira Women's Health Inc., 2022. All Rights Reserved.

Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements include, am

Slide 3: Our Strategy is Sound, the Path Forward is Clear
Our Strategy is Sound, the Path Forward is Clear 2022 is about Focused Execution Accelerated Adoption and Volume Launch Development Operational Excellence Copyright (C) Aspira Women's Health Inc., 2022. All Rights Reserved. 3

Slide 4: Leadership Team with Extensive Life Sciences Experience
Leadership Team with Extensive Life Sciences Experience Management Board of Directors Nicole Sandford Robert Beechey Charles Dunton Ryan Phan Valerie Palmieri James LaFrance Robert Auerbach CEO, President & Director CFO Interim CMO CSO & COO Executive Chairwoman Lead Independent Director Director Je

Slide 5: Market Leader in Socially Responsible Health Innovation for Women
Market Leader in Socially Responsible Health Innovation for Women The only publicly traded company focused exclusively on women’s gynecological health Proudly Leading in Board and Executive Diversity Health Equity is a Core Value • ~60% of Medicaid lives covered by our OVA1plus® ovarian cancer risk

Slide 6: About Aspira Women's Health Highlights
About Aspira Women’s Health Highlights Commercially Revenue-generating test for ovarian cancer risk assessment developed using Available Test proprietary technology Health Committed to ensuring best standard of care is available to all women Equity Focused Compelling pipeline of gynecological diagno

Slide 7: Recent Developments
Recent Developments Collaboration with BioReference Laboratories, the largest full-service specialty laboratory in the U.S., to offer OVA1plus • Established a national partnership to co-market and distribute OVA1Plus with BioReference Laboratories, Inc. the largest full-service specialty laboratory

Slide 8: Recent Developments
Recent Developments Leveraging academic resources to cost-effectively enhance AWH products • Exclusive sponsored research agreement with Dana-Farber Cancer Institute further builds on our prior R&D efforts, accessing resources to accelerate the development of EndoCheck, an aid in the diagnosis of en

Slide 9: Significant Market Opportunity
Significant Market Opportunity OvaWatch will address an unmet need by expanding the patient population beyond those planned for surgery OVA1Plus Pelvic Mass – Annual Patient (Planned For Surgery) Population: = 300 to 400K OVAWatch Pelvic Mass Annual Patient (Initial Clinical Assessment) Population:

Slide 10: Most Ovarian Cancer Detected at Late-Stage – When It's Most Deadly
Most Ovarian Cancer Detected at Late-Stage – When It’s Most Deadly Presentation Stage I Stage II Stage III Stage IV Stage Local Pelvic Regional nodes Distant spread Incidence 15% 21% 59% 6% Five Year 92% 75% 29% 24% Survival Rate www.SEER.Cancer.gov Ovarian Cancer Late-Stage Diagnosis >65% Late-Stag

Slide 11: Current Standard of Care for Assessing Cancer Treatment: Limitations
Current Standard of Care for Assessing Cancer Treatment: Limitations Blood Tumor Tissue Clinical Assessment Marker Analysis Physical exam and ultrasound CA 125 (off-label) Pre-operative biopsy not ROMA™ (alternative) recommended Limitations: Subjective results and Limitations: Low sensitivity and Li

Slide 12: A Better Blood Risk Assessment
A Better Blood Risk Assessment OVA products demonstrate better performance in early-stage risk detection 5% OVA risk assessment products 31% 31% substantially improve the effectiveness of clinical 95% assessment in stratifying 69% the risk of Stage 1 and Stage 2 malignancy for women with pelvic mass

Slide 13: Commercial Strategy
Sales Force Optimization Adoption and Commercial Strategy Coverage Product Expansion Expansion and Commercialization of our OVA products is a top priority for 2022 Platforms and Partnerships Commercial Strategy Focus Sales Force Optimization Targeting gynecological 26 full-time specialists, Expanded

Slide 14: OVA Test Volume
Sales Force Optimization Adoption and OVA Adoption Since Introduction of 2nd-Generation Test Coverage Product Expansion We have driven strong physician adoption over the past four years – despite experiencing episodic headwinds Platforms and resulting from the COVID-19 pandemic Partnerships OVA volu

Slide 15: Market Access
Sales Force Optimization Adoption and Market Access Coverage Product Expansion We aim to make OVA products available to all women Platforms and Partnerships 168 Million Commercial lives covered ~48 Million Medicaid lives covered Commercial coverage also includes Medicare Advantage plans ■ Covered sp

Slide 16: OVAWatch Third-Generation OVA Product
Sales Force Optimization Adoption and Coverage Product Expansion OVAWatch is our 3rd-generation OVA product. It is a non-invasive laboratory developed test to be used in Platforms and conjunction with clinical assessment to determine the risk of ovarian cancer for patients with an adnexal mass Partn

Slide 17: Endometriosis Presents an Unmet Need and Market Opportunity
Sales Force Optimization Adoption and Endometriosis Presents an Unmet Need and Market Opportunity Coverage Product Expansion Platforms and Partnerships Health cost 6-7 million • EndoCheck is our in-development burden women affected in the U.S. by endometriosis2 test for endometriosis targeted for fo

Slide 18: Aspira Synergy: Phases of the Typical Client Relationship Lifecycle
Sales Force Aspira Synergy(SM): Phases of the Typical Client Relationship Optimization Adoption and Lifecycle Coverage Product Expansion Platforms and Partnerships Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Agreement Implementation Launch Adoption/Scale Optimization Women’s Care Sales and Adoption: Rev

Slide 19: Financial Performance Snapshot
Financial Performance Snapshot Q2 2021 vs. Q2 2022 Q1 2022 vs. Q2 2022 Key Growth Drivers Cash Position OVA Product Volume OVA Product Volume Expansion of Direct Salesforce Cash as of June 30, 2022 and New Strategic Partnerships $20.7M • Recent additions to the direct 5,411 salesforce, as well as ne

Slide 20: In Conclusion ...
In Conclusion ... Our strategy is sound, the path forward is clear. 2022 is about Focused Execution Accelerated Adoption and Volume Launch Development Operational Excellence Copyright (C) Aspira Women's Health Inc., 2022. All Rights Reserved. 20
Source: Internet Archive copy of ir.aspirawh.com
More decks from Aspira Women's Health Inc.
Investor Presentation (December 2025)35 slides · Dec 31, 2025
Investor Presentation (January 2025)26 slides · Jan 13, 2025
Technical Presentation (October 2024)47 slides · Oct 29, 2024
Investor Day (October 2024)42 slides · Oct 29, 2024
Investor Presentation (September 2024)30 slides · Sep 13, 2024
Fact Sheet (June 2024)2 slides · June 2024